Biguanides (i.e., N=c(-n)-n(n-)c=n) Patents (Class 514/635)
-
Publication number: 20120282336Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: ApplicationFiled: November 12, 2010Publication date: November 8, 2012Applicants: ASTRAZENECA UK LIMITED, BRISTOL-MYERS SQUIBB COMPANYInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Publication number: 20120283333Abstract: Ophthalmic compositions that comprise 0.5 ppm to 15 ppm ?-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-?-tris(2-hydroxyethyl) ammonium chloride; 0.005 wt. % to 0.05 wt. % hyaluronic acid; citrate, citric acid or a mixture thereof; and 0.01 wt. % to 0.8 wt. % of an amphoteric surfactant of general formula I wherein R1 is R or —(CH2)n-NHC(O)R, wherein R is a C8-C30alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R2 and R3 are each independently selected from the group consisting of hydrogen and C1-C4alkyl; R4 is a C2-C8alkylene optionally substituted with hydroxyl; and Y is CO2? or SO3?. The invention is also direct to the use of the ophthalmic compositions to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.Type: ApplicationFiled: July 20, 2012Publication date: November 8, 2012Inventors: Erning Xia, Susan E. Burke, Srini Venkatesh, Vicki L. Barniak
-
Publication number: 20120283299Abstract: A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK? and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.Type: ApplicationFiled: January 6, 2011Publication date: November 8, 2012Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Chang Hee Min, Young Woong Kim, Min Seok Kang, Byung Kyu Oh, Se Hwan Park, Yong Eun Kim, Duck Kim, Ji Sun Lee, Ju Hoon Oh
-
Publication number: 20120283332Abstract: Provided is a transdermal metformin that is an effective alternative treatment modality in patients with insulin resistance. Transdermal metformin can be used in conditions where oral metformin is indicated such as Type 2 diabetes mellitus, pre-diabetes, polycystic ovarian syndrome, and other known diabetes associated disorders. One advantage of using transdermal metformin is its ability to bypass the gastrointestinal system. This allows the drug to not have the gastrointestinal side-effects associated with oral metformin. A surprising advantage of using transdermal metformin in accordance with this disclosure is a 90% decrease in dosage from the oral preparation.Type: ApplicationFiled: May 12, 2010Publication date: November 8, 2012Applicant: OHIO UNIVERSITYInventors: Chase A. Scarbrough, Stanley S. Scarbrough, Jay Shubrook
-
Patent number: 8304454Abstract: Biguanide bonded within a cellulose sponge inhibits or prevents the growth of microorganisms such as bacteria, mold, and fungus within the cellulose sponge over the useful life of the cellulose sponge.Type: GrantFiled: December 8, 2008Date of Patent: November 6, 2012Assignee: 3M Innovative Properties CompanyInventor: Myhanh T. Truong
-
Publication number: 20120269772Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: ApplicationFiled: June 29, 2012Publication date: October 25, 2012Applicant: Camurus ABInventors: Krister THURESSON, Fredrik TIBERG, Markus JOHANSSON, Ian HARWIGSSON, Fredrik JOABSSON, Markus JOHNSSON
-
Publication number: 20120270917Abstract: Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein.Type: ApplicationFiled: July 30, 2010Publication date: October 25, 2012Applicant: The Trustees of the University of PennsylvaniaInventors: William F. DeGrado, Jun Wang
-
Publication number: 20120270909Abstract: In an embodiment, the barrier-forming composition includes a carbohydrate gum, a humectant, and an antimicrobial agent. The composition furthermore meets the following requirements: about 0.01%?C?about 0.4%; about 4.5%?H?about 65%; and 0.050%<A; or about 0%?C?about 0.4%; about 55%?H?about 65%; and 0.050%<A. C is the carbohydrate gum; H is the humectant; and A is the antimicrobial agent. All percentages are by weight of the total composition. In an embodiment the barrier-forming composition has an Rf value in water of 0 to about 0.25.Type: ApplicationFiled: April 17, 2012Publication date: October 25, 2012Inventors: Brian Vincent Sokol, Afif Mahmoud Ghannoum
-
Publication number: 20120258064Abstract: Moisturizers are mixtures of chemicals specifically designed to make the external layers of the skin (epidermis) softer and more pliable, by increasing its hydration (water) content and reducing evaporation. Loss of moisture in the stratum corneum causes dry skin and compromises its barrier function. Therefore, maintaining the hydration level of this layer is essential for healthy skin. For individuals who wash hands frequently or have dry skin (e.g. due to age or diabetes) using a moisturizer may be important. The personal care composition described herein provides a moisturizing system that does not have a negative effect on skin such as that which can be attributed to surfactants.Type: ApplicationFiled: April 6, 2012Publication date: October 11, 2012Inventors: Dipak Narula, Vinod K. Narula
-
Publication number: 20120258157Abstract: A process for the treatment of a synthetic textile (T) with a cationic biocide (B) and at least one anionic polymer (P) which comprises the step of treating the synthetic textile with an aqueous composition containing the cationic biocide (B) in a concentration (c1) and containing the anionic polymer (P) in a concentration (c2), wherein the concentrations (c1) and (c2) are selected so that the ratio (R) of negative charges of the anionic polymer (P) to the positive charges of the cationic biocide (B) is between 10:1 and 1:1, leads to textiles with long term biocide activity.Type: ApplicationFiled: April 5, 2012Publication date: October 11, 2012Applicant: BASF SEInventors: Sebastian Koltzenburg, Thomas Gottschalk, Volodymyr Boyko, Glen Thomas Cunkle
-
Publication number: 20120237612Abstract: Ultrasound gels and methods for making ultrasound gels are disclosed herein. According to one embodiment, a gel for use with an ultrasound machine comprises glycerol and a composition. The composition in-turn comprises chlorhexidine gluconate and propylene glycol.Type: ApplicationFiled: March 14, 2012Publication date: September 20, 2012Inventor: Jeffrey L. Lampe
-
Publication number: 20120237590Abstract: Compositions and methods for treating type 2 diabetes and its sequelae by intravenous or subcutaneous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly one or more anti-diabetic agents to human subjects are disclosed herein. The composition of the present invention may be used to: (i) treat patients with diabetes in advanced stages with evidence of any or all encephalopathy, retinopathy, nephropathy, pancreatitis or neoplasias; (ii) treat patients with diabetic disease status without symptomatic or pathologic evidence of associated sequelae but requiring better glycemic control than that offered by standard of care anti-diabetic; and (iii) patients with objective signs or symptoms of sequelae from diabetes of anti-diabetic drugs. One three-drug combination of the present invention includes a slow release PLGA-curcumin and an oral gliptin (DPP-4)-inhibitor or any incretin-mimetic and metformin.Type: ApplicationFiled: March 15, 2012Publication date: September 20, 2012Applicant: SIGNPATH PHARMA INC.Inventor: Lawrence Helson
-
Publication number: 20120238635Abstract: The present invention relates to a stable antiseptic solution comprising: a di(4-chlorophenyldiguanido) compound or a pharmaceutically acceptable salt thereof, wherein said di(4-chlorophenyldiguanido) compound or a pharmaceutically acceptable salt thereof is a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to a process for preparing said antiseptic solution.Type: ApplicationFiled: March 14, 2012Publication date: September 20, 2012Applicant: Combino Pharm, S.L.Inventors: Marina Puigvert Colomer, Sergio Lloret Perez
-
Publication number: 20120231080Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.Type: ApplicationFiled: May 18, 2012Publication date: September 13, 2012Applicant: VALEANT INTERNATIONAL(BARBADOS) SRLInventor: Steven FRISBEE
-
Publication number: 20120232006Abstract: The invention relates to a process for producing polyurethane foams, by frothing and drying mixtures of specific polyurethane dispersions and crosslinkers.Type: ApplicationFiled: April 17, 2012Publication date: September 13, 2012Applicant: Bayer MaterialScience AGInventors: Jan Schönberger, Michael Mager, Thorsten Rische, Sebastian Dörr, Thomas Feller, Michael Heckes, Melita Dietze, Burkhard Fugmann
-
Publication number: 20120231081Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.Type: ApplicationFiled: May 18, 2012Publication date: September 13, 2012Applicant: VALEANT INTERNATIONAL (BARBADOS) SRLInventor: Steven FRISBEE
-
Publication number: 20120232156Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.Type: ApplicationFiled: May 18, 2012Publication date: September 13, 2012Applicant: VALEANT INTERNATIONAL(BARBADOS) SRLInventor: Steven E. FRISBEE
-
Publication number: 20120232037Abstract: Disclosed herein are methods for treating obesity, metabolic syndrome, diabetes, or a combination of these conditions. The methods include selecting a subject with obesity, metabolic syndrome, or diabetes and administering to the subject a therapeutically effective amount of a composition comprising a compound that specifically inhibits hepatic protein kinase C (PKC)-?, thereby treating the obesity, metabolic syndrome, or diabetes in the subject. In some embodiments the compound that specifically inhibits hepatic PKC-? includes a thio-gold compound (such as aurothiomalate, aurothioglucose, and auranofin) or a derivative thereof, or a pharmaceutically acceptable salt thereof. In other embodiments, the compound that specifically inhibits hepatic PKC-? includes 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-[1R-(1?,2?,3?,4?)] (ICAPP) or a derivative thereof, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 9, 2012Publication date: September 13, 2012Inventor: Robert V. Farese
-
Patent number: 8263121Abstract: The present invention provides a solid preparation containing an insulin sensitizer and an active ingredient (except insulin sensitizers), which shows in vivo dissolution behavior of an insulin sensitizer, which is similar to the dissolution behavior of an insulin sensitizer from “a solid preparation containing an insulin sensitizer alone as an active ingredient”. The present invention provides a solid preparation containing (1) a layer containing an insulin sensitizer, and (2) a layer containing (a) an active ingredient (except insulin sensitizers), (b) microcrystalline cellulose having a mean particle size of 5-25 ?m, (c) microcrystalline cellulose having a mean particle size of 30-100 ?m and (d) polyvinylpyrrolidone K-90.Type: GrantFiled: April 13, 2005Date of Patent: September 11, 2012Assignee: Takeda Pharmaceutical Company LimitedInventors: Masahiko Koike, Hiroyoshi Koyama, Naoru Hamaguchi
-
Publication number: 20120220664Abstract: Disclosed herein is a method for treating a tumor in a subject in need thereof comprising administering an enhancing amount of metformin and a reduced amount of one or more chemotherapeutic agents. One example of an enhancing amount of metformin is about 250 mg/day. Also disclosed is a Untreated method for preventing cancer or delaying the recurrence of cancer in a subject comprising administering an effective amount of metformin to the subject. In one example of such a method, the amount of metformin is about 75 mg/day. Also disclosed is a composition comprising an enhancing amount of metformin, and a reduced amount of one or more chemotherapeutic agents and a pharmaceutically acceptable carrier. Kits comprising metformin and one or more chemotherapeutic agents are also disclosed.Type: ApplicationFiled: August 25, 2010Publication date: August 30, 2012Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Kevin Struhl, Heather Hirsch, Dimitrios Iliopoulos
-
Publication number: 20120213832Abstract: A dental curable composition comprises (A) a polymerizable monomer and (B) an organic amine-based polymerization initiator, wherein (A?) a long-chain polymerizable monomer having a chain length of 17 or more atoms is contained in the component (A) and/or (C) a soft resin material are/is contained in the composition, and when the amount (parts by weight) based on 100 parts by weight of the component (A) of the component (A?) is represented by [a?] and the amounts (parts by weight) based on 100 parts by weight of the total of the components (A) and (B) of the components (A), (B) and (C) are represented by (a), (b) and (c), respectively, 70?(a)?99.99, 0.01?(b)?5 30, 1?[a?]/5+(c)/1, 0?[a?]?95, and 0?(c)?250.Type: ApplicationFiled: October 22, 2010Publication date: August 23, 2012Inventors: Tatsuya Ori, Haruka Nishitani, Sayuri Iwasaki, Yuya Yamamoto, Chidzuru Nishimoto
-
Publication number: 20120214821Abstract: The invention, in some aspects, relates to methods for predicting a subject's risk of developing a glucose-related metabolic disorder, e.g., diabetes. In some aspects, the invention relates to methods for selecting and monitoring a treatment for a glucose-related metabolic disorder, e.g., diabetes.Type: ApplicationFiled: January 20, 2012Publication date: August 23, 2012Applicants: THE BROAD INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATIONInventors: Robert Gerszten, Thomas Wang, Eugene Rhee, Clary Clish
-
Publication number: 20120202888Abstract: Measurement of circulating C-peptide levels is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of fatal prostate cancer.Type: ApplicationFiled: October 11, 2011Publication date: August 9, 2012Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: Jing MA
-
Patent number: 8236345Abstract: A pharmaceutical composition, comprising a thiazolidinedione, such as Compound (I), metformin hydrochloride and a pharmaceutically acceptable carrier, wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.Type: GrantFiled: July 18, 2007Date of Patent: August 7, 2012Assignee: SmithKline Beecham LimitedInventors: Karen Lewis, Nicola Jayne Lilliott, Donald Colin MacKenzie
-
Patent number: 8232281Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.Type: GrantFiled: May 4, 2007Date of Patent: July 31, 2012Assignee: Boehringer Ingelheim International GmbHInventors: Klaus Dugi, Frank Himmelsbach, Michael Mark
-
Publication number: 20120190618Abstract: The invention provides a method and a pharmaceutical composition in the form of a hydroalcoholic solution in which at least one hypoglycemia-inducing/insulinotropic active principle is dissolved in a stable and complete manner at a dosage that is reduced by 30% to 50% compared with the usual oral unit dosage, for its trans-buccal mucosal application in the spot treatment of postprandial hyperglycemia in type II diabetes in man or animals. The invention also pertains to a method of preparing said formulation and to its specific use in the spot treatment of postprandial hyperglycemia (PPHG) in the context of type II diabetes.Type: ApplicationFiled: July 7, 2010Publication date: July 26, 2012Inventors: Philippe Perovitch, Marc Maury, Jean-Pierre Dumonteix
-
Publication number: 20120190715Abstract: Compositions and methods for treating disordered tissues, such as caused by pathogens and/or by toxins. The treatment compositions include an anti-infective active agent, a liquid carrier, and benzocaine in an amount so that the treatment composition penetrates more quickly into disordered tissue compared to the treatment composition in the absence of the benzocaine. In addition, the benzocaine can increase residence time of the anti-infective active in the treatment area. The preferred anti-infective active agent can be an organohalide, such as a quaternary ammonium halide compound, an example of which is benzalkonium chloride. The treatment compositions and methods may employ the use of an applicator adapted for use in promoting penetration of the treatment composition and/or agitation of the disordered tissue to further enhance penetration.Type: ApplicationFiled: January 24, 2011Publication date: July 26, 2012Inventors: B. Ron Johnson, James P. McCarthy
-
Publication number: 20120184624Abstract: The present invention relates to a method of treating and/or preventing Alzheimer's disease and/or other tauopathies.Type: ApplicationFiled: December 16, 2011Publication date: July 19, 2012Inventors: Susann Schweiger, Rainer Schneider, Hartmut Glossmann
-
Publication number: 20120177720Abstract: A wound dressing includes one or more layers containing a first anti-microbial agent and optionally at least one of: a chelating agent, a second anti-microbial agent, a zinc-containing agent, a cell-signaling agent, and an additional active ingredient or agent.Type: ApplicationFiled: March 21, 2012Publication date: July 12, 2012Applicant: Tyco Healthcare Group LPInventors: Harish A. Patel, Hansen P. Swaniker, David G. Heagle, Kate Ward, Alain Tranchemotagne
-
Publication number: 20120177730Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.Type: ApplicationFiled: January 6, 2012Publication date: July 12, 2012Applicant: Elcelyx Therapeutics, Inc.Inventors: Alain D. BARON, Martin R. BROWN, Christopher R.G. JONES, Nigel R.A. BEELEY, Mark S. FINEMAN
-
Publication number: 20120172451Abstract: The present invention relates to a cleaning fluid, in particular a cleaning fluid for cleaning surfaces.Type: ApplicationFiled: December 16, 2011Publication date: July 5, 2012Inventor: Navjeet Kaur MATHARU
-
Publication number: 20120157540Abstract: The present invention relates to disinfectant formulations containing: (i) an antimicrobial active agent selected from the group consisting of biguanides, monoguanides, and combinations thereof; (ii) a compound selected from the group consisting of a dialkyldimethyl ammonium salt, an alkyldimethylbenzyl ammonium salt, an alkyldimethyl(ethylbenzyl) ammonium salt, and combinations thereof wherein the formulation is free of sequestrants. The total amount of the component (i) and the component (ii) is from about 500 ppm to about 1000 ppm based on the weight of the disinfectant formulation, and the component (i) and the component (ii) are present in a range of weight ratios between about 1:1 and about 1:10.Type: ApplicationFiled: January 17, 2012Publication date: June 21, 2012Inventors: Paula Louise McGeechan, William Woods
-
Publication number: 20120157399Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.Type: ApplicationFiled: February 22, 2012Publication date: June 21, 2012Applicant: Satiogen Pharmaceuticals, Inc.Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
-
Publication number: 20120156274Abstract: The present invention describes microbicidal hydrophilic polyurethane foams endowed with polyhexamethylenebiguanide (PHMB) and/or its hydrochloride and also a superabsorbent, wound contact materials obtainable therefrom and processes for producing the therapeutically endowed polyurethane foams and the wound contact materials obtainable therefrom.Type: ApplicationFiled: February 24, 2012Publication date: June 21, 2012Applicant: BAYER INNOVATION GMBHInventors: Burkhard Fugmann, Melita Dietze
-
Publication number: 20120150131Abstract: A medical device includes a base material and chlorhexidine or a pharmaceutically acceptable salt thereof disposed in the base material sufficient to reduce microbial growth. The base material includes a polymer having a silicone monomer and a urethane monomer.Type: ApplicationFiled: December 9, 2010Publication date: June 14, 2012Applicant: Teleflex Medical IncorporatedInventors: Hiep Do, Joel Rosenblatt
-
Publication number: 20120148530Abstract: An inexpensive, easily available, and convenient method of treating or preventing a virus infection is provided. The present invention relates to a method for the treatment or prevention of virus infections using polybiguanide-based compounds administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof The invention relies on the unique biochemical reaction in which polybiguanide-based compounds interfere with the spread of virus within or between organisms. The compositions and formulations described in the present invention are effective means to reduce the infectivity of the human immunodeficiency virus type 1 (HIV-1), and human herpes simplex viruses, and also to kill the causative organisms of many other sexually transmitted diseases (STDs).Type: ApplicationFiled: June 21, 2010Publication date: June 14, 2012Applicant: Novaflux Biosciences, Inc.Inventors: Mohammed E. Labib, Richard F. Stockel
-
Publication number: 20120150033Abstract: An antimicrobial ultrasound transmitting gel has an ultrasound-transmitting gel and an effective amount of one or more antimicrobial additives. The gel may further include one or more skin cleansers to provide a gel that may be used to both decontaminate the skin and for the performance of the ultrasound.Type: ApplicationFiled: July 8, 2011Publication date: June 14, 2012Inventor: LOREN CURTIS RAUCH
-
Publication number: 20120148651Abstract: According to one embodiment, a coagulant comprising calcium nitrate and an antimicrobial agent is disclosed. The coagulant may be used in the molding process to releasably bond the substrate material to the mold and to bond to the antimicrobial to the substrate material.Type: ApplicationFiled: December 10, 2010Publication date: June 14, 2012Applicant: MEDLINE INDUSTRIES INC.Inventors: Samuel T. Amdur, Min Yao
-
Patent number: 8198320Abstract: The present invention relates to a method for controlling blood glucose level and a method for the prophylaxis or treatment of diabetes mellitus and/or its complications. The present invention further relates to an anti-diabetic formulation for controlling blood glucose level and/or for the prophylaxis or treatment of diabetes mellitus and/or its complications.Type: GrantFiled: December 31, 2008Date of Patent: June 12, 2012Assignee: Taipei Medical UniversityInventors: Yu-Chih Liang, Der-Zen Liu, Ling-Fang Hung, Pei-Jung Lin, Nai-Qi Chen, Yu-Chien Chen
-
Publication number: 20120141570Abstract: A paper product having an antimicrobial composition dispersed with the substrate is provided. In particular, a paper towel such as those found in public washrooms or institutions comprises an antimicrobial composition. The substrate can also be a facial tissue, kitchen towel, serviette or any type of personal hygiene product. The antimicrobial composition preferably comprises a phenol-derived antimicrobial agent. The paper products of the present invention appear dry to the touch.Type: ApplicationFiled: February 9, 2012Publication date: June 7, 2012Inventor: Philip Buder
-
Publication number: 20120135080Abstract: The invention provides core-shell magnetic particles comprising a magnetic core and a functional shell, methods for making same, methods of separation using same, methods for using same, and devices comprising same. The particles and methods of the invention are useful for targeting and removing substances of interest that may be found in complex mixtures.Type: ApplicationFiled: November 4, 2011Publication date: May 31, 2012Applicant: Massachusetts Institute of TechnologyInventors: Lev E. Bromberg, Emily P. Chang, Trevor Alan Hatton
-
Publication number: 20120135952Abstract: The present invention provides metformin butyric acid salt, a method of preparing the same, and pharmaceutical compositions and combinations containing the same. The metformin butyric acid salt according to the present invention has an excellent pharmacological effect as compared with metformin hydrochloride and is capable of achieving a therapeutic purpose by administering an amount less than metformin hydrochloride. Furthermore, the metformin butyric acid salt has excellent physicochemical properties, such as solubility, stability, hygroscopicity and adsorption preventing property, in processibility of formulations and thereby is capable of being usefully utilized as a pharmaceutically acceptable salt of the metformin.Type: ApplicationFiled: July 16, 2010Publication date: May 31, 2012Applicant: Hanall Biopharma Co., Ltd.Inventors: Sung Wuk Kim, Sung Soo Jun, Changhee Min, Min Seok Kang, Yong Eun Kim, Ja Seong Koo
-
Patent number: 8188151Abstract: The subject invention provides compositions and methods for treating diabetes in patients. In a preferred embodiment, the invention provides compositions methods for treating diabetes and/or preventing or alleviating complications associated with diabetes. Specifically exemplified herein is the concurrent administration of a cysteamine compound with at least one additional therapeutic agent to prevent and/or treat diabetes as well as prevent and/or treat complications associated with diabetes. In a preferred embodiment, oral administration of cysteamine hydrochloride with Metformin to a patient diagnosed with diabetes can substantially regulate the patient's glucose metabolism and insulin sensitivity.Type: GrantFiled: October 28, 2008Date of Patent: May 29, 2012Assignee: Omega Bio-Pharma (I.P.3) LimitedInventors: Bill Piu Chan, Gary Kwan Po Wong, Jinxian Xu, Francis Chi
-
Publication number: 20120128793Abstract: Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer region, an antimicrobial agent for providing resistance to microbial growth and a microbial adhesion/biofilm synthesis inhibitor for inhibiting the attachment of microbes and the synthesis and accumulation of biofilm on the surface of the medical device.Type: ApplicationFiled: January 24, 2012Publication date: May 24, 2012Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: Kathleen M. Miller, Gregory T. Sydney, Kurt Geitz, Peter L. Dayton, Ronald A. Sahatjian
-
Publication number: 20120122991Abstract: The invention relates to modulation of LKB1 or AMP kinase protein activity for treating disorders including diabetes and cancer. The invention also relates to screening for agents that modulate the activity of LKB1 or AMP kinase protein, which are useful in the treatment of diabetes and cancer, as well as preparing compounds for treatment of diabetes and cancer.Type: ApplicationFiled: January 20, 2012Publication date: May 17, 2012Applicants: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Lewis C. Cantley, Reuben J. Shaw, Nabeel Bardeesy, Ronald A. Depinho
-
Publication number: 20120121665Abstract: Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer region, an antimicrobial agent for providing resistance to microbial growth and a microbial adhesion/biofilm synthesis inhibitor for inhibiting the attachment of microbes and the synthesis and accumulation of biofilm on the surface of the medical device.Type: ApplicationFiled: January 24, 2012Publication date: May 17, 2012Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: Kathleen M. Miller, Gregory T. Sydney, Kurt Geitz, Peter L. Dayton, Ronald A. Sahatjian
-
Publication number: 20120101166Abstract: Composition and method for irrigating a prepared dental root canal. The composition is an aqueous composition of ethylenediamine tetraacetic acid, chlorhexidine or orally acceptable addition salt, and N-cetyl-N,N,N-trimethylammonium bromide, and is effective for simultaneous smear layer removal and disinfection.Type: ApplicationFiled: December 19, 2011Publication date: April 26, 2012Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventor: Markus Haapasalo
-
Publication number: 20120101155Abstract: The present invention provides for compositions and methods that may offer protection from irritants as well as antimicrobial protection. Preferred embodiments of the invention include topical antimicrobial compositions that lack conventional antibiotics or preservatives, wherein the antimicrobial benefit is created by essential oils (or their active ingredients), emollient solvents and, in some instances, anti-inflammatory agents.Type: ApplicationFiled: January 4, 2012Publication date: April 26, 2012Inventors: Shanta M. Modak, Trupti Gaonkar, Milind Shintre
-
Publication number: 20120100199Abstract: Provided is a method for treating a periodontal disease affecting a periodontal pocket of a patient. The method includes inserting an oral delivery device into the periodontal pocket at a frequency of about once every 4 days to about once every 6 weeks. The oral delivery device is a controlled release solid unit dosage form suitable for insertion into a periodontal pocket of a patient, including a therapeutically effective amount of at least one anti-inflammatory agent, at least one antibacterial agent, or the combination of at least one anti-inflammatory agent and at least one antibacterial agent.Type: ApplicationFiled: October 20, 2011Publication date: April 26, 2012Applicant: DEXCEL PHARMA TECHNOLOGIES LTD.Inventors: Avi AVRAMOFF, Eyal SHOSHANI, Adel PENHASI, Dan OREN
-
Publication number: 20120094942Abstract: Provided herein are methods of modulating hormone concentrations in a subject comprising the administration of a composition comprising a chemosensory receptor ligand, wherein the composition is adapted to deliver the ligand to one or more regions of the intestine of said subject. Also provided are methods directed to the modulation of circulating concentrations of one or more of GLP-1 (total), GLP-1 (active), GLP-2, oxyntomodulin, PYY (total), PYY 3-36, CCK, GIP, insulin, C-peptide, glycentin, uroguanylin amylin, and ghrelin (total), ghrelin (active) and glucagon.Type: ApplicationFiled: October 18, 2011Publication date: April 19, 2012Applicant: Elcelyx Therapeutics, Inc.Inventors: Alain D. BARON, Martin R. Brown, Christopher R.G. Jones, Mark S. Fineman